



AstraZeneca

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10-5-05 PCT
JCOS Rec'd PCT/PTO 04 OCT 2005 #3

Applicant: Mortlock, Andrew Austen	371 Filing Date: June 17 th , 2005
Application No.: 10/539,483	Attorney Docket No.: 100936 1P-US
Customer No.: 44992	Examiner: Not yet assigned
Title: Therapeutic Quiniazoline Derivatives	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 4th October 2005

Lucy Padget

Signature
Lucy Padget

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

AstraZeneca R&D Boston
A business unit of AstraZeneca Pharmaceuticals LP
35 Gatehouse Drive
Waltham MA 02451
USA

Tel +1 781-839-4000
Fax +1 781-839-4500


REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed before the mailing of the first Office Action on the merits.

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100936-1P US.

Respectfully submitted,



Name: Lucy Padgett
Dated: 4th October 2005
Reg. No.: L0074
Phone No.: 781-839-4182

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 01760

Enclosures: Form SB08A
Form SB08B
Documents



Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET 1 of 1

Complete if Known

Application Number	10/539,483
Filing Date	June 17, 2005
First Named Inventor	MORTLOCK, Andrew
Art Unit	100/XXXXXX 1624
Examiner Name	XXXXXXXXXX T. Truong
Attorney Docket No.	100936-1P US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
/T.N./	A1	US6258820 B1	07-10-2001	PARKER HUGHES INSTITUTE Uckun et. al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ³
		Country Code ⁴ - Number ⁵ - Kind Code ⁶ (if known)				
/T.N./	AA	WO 01/21597 A1	03-29-2001	ASTRAZENECA AB		<input type="checkbox"/>
/T.N./	AB	WO 01/21594 A1	03-29-2001	ASTRAZENECA AB		<input type="checkbox"/>
/T.N./	AC	WO 00/56720 A1	09-28-2000	PARKER HUGHES INSTITUTE		<input type="checkbox"/>
/T.N./	AD	WO 03/00188 A2	01-03-2003	ARIAD PHARMACEUTICALS, INC		<input type="checkbox"/>
/T.N./	AE	WO 01/21596 A1	03-29-2001	ASTRAZENECA AB		<input type="checkbox"/>
/T.N./	AF	WO 95/15758 A1	06-15-1995	RHONE-POULENC RORER PHARMACEUTICALS, INC		<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
Examiner Signature	/Tamthom Truong/			Date Considered	08/11/2008	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.